Janssen Pharmaceutical Companies Janssen Has sped-up its COVID-19 Vaccine Candidate initiation.

From Johnson & Johnson – Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, said, “Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to further accelerate the clinical development of our investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Simultaneously, we are continuing our efforts to build important global partnerships and invest in our vaccine production technology and manufacturing capabilities. Our goal is to ensure we can deliver a vaccine to the world and protect people everywhere from this pandemic.”

News and Information of today presented by The Law Offices of Michael O’Day Car Accident Attorneys in Pittsburgh Pennsylvania.